Diabetic Nephropathy News and Research

RSS

Diabetic nephropathy is kidney disease or damage that results as a complication of diabetes.

JAMA commentary argues that vitamin therapy still plays a role in reducing stroke

A commentary by Dr. David Spence of The University of Western Ontario and Dr. Meir Stampfer of the Harvard School of Public Health in today's Journal of the American Medical Association (JAMA) argues that vitamin therapy still has a role to play in reducing stroke.

22 Dec 2011

ChemoCentryx commences CCX140 Phase II trial in diabetic nephropathy

ChemoCentryx, Inc. today announced the initiation of a Phase II clinical trial for CCX140, an orally-administered small molecule for the treatment of diabetic kidney disease.

9 Dec 2011

Concert to initiate CTP-499 Phase 2 diabetic nephropathy clinical trial in 2012

Concert Pharmaceuticals, Inc. today announced data from a Phase 1 clinical trial of CTP-499, a novel agent for the potential treatment of diabetic nephropathy.

14 Nov 2011

Positive results from ChemoCentryx CCX354 Phase II study on RA

ChemoCentryx, Inc., today announced that it reported positive Phase II results for CCX354 at the Annual Meeting of the American College of Rheumatology.

9 Nov 2011

Arginase-2 enzyme plays a major role in diabetic nephropathy

The enzyme arginase-2 plays a major role in kidney failure, and blocking the action of this enzyme might lead to protection against renal disease in diabetes, according to researchers.

5 Nov 2011

JDC receives NIDDK grant for research into diabetic retinopathy, kidney disease

Joslin Diabetes Center has received a $3.9 million DP3 grant from the National Institute of Diabetes and Digestive and Kidney Diseases, part of the National Institutes of Health, to identify protective factors that enable many Joslin 50-Year Medalists to remain free of commonly occurring diabetes complications.

3 Nov 2011

Sulodexide drug fails to benefit diabetes patients with kidney disease

What was hoped to be a promising new drug to protect the kidneys has failed to benefit diabetes patients with kidney disease, according to a study appearing in an upcoming issue of the Journal of the American Society Nephrology.

28 Oct 2011

Data from Concert Pharmaceuticals' CTP-499 study to be presented at ASN Kidney Week 2011

Concert Pharmaceuticals, Inc. today announced that three abstracts relating to CTP-499, its clinical candidate for the potential treatment of diabetic nephropathy, have been accepted for poster presentations at the American Society of Nephrology's (ASN) Kidney Week 2011.

19 Oct 2011

ChemoCentryx commences CCX168 Phase II trial in ANCA-associated vasculitis

ChemoCentryx, Inc., today announced the initiation of a Phase II clinical trial for CCX168, an orally-administered small molecule for the treatment of anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV), a disease which can lead to renal and pulmonary failure.

18 Oct 2011

UC San Diego professor receives NIDDK grant to study kidney complications related to diabetes

Kumar Sharma, MD, FAHA, professor of medicine at the University of California, San Diego School of Medicine and director of the Center for Renal Translational Medicine, has received a $5.9 million grant from the National Institute of Diabetes and Digestive and Kidney Diseases, part of the National Institutes of Health, to study kidney complications related to type 1 and type 2 diabetes.

1 Oct 2011

Lack of kidney dopamine leads to high blood pressure and shorter life span

The neurotransmitter dopamine is best known for its roles in the brain - in signaling pathways that control movement, motivation, reward, learning and memory.

20 Jul 2011

ASN President discusses latest information about diabetic nephropathy at ADA

ASN President Dr. Joseph V. Bonventre, MD, PhD, spoke at the American Diabetes Association's annual meeting, 71st Scientific Session, this June in San Diego. Dr. Bonventre was featured at a symposium entitled "New Concepts in Diagnosing and Treating Diabetic Nephropathy."

6 Jul 2011

Relypsa initiates dosing in RLY5016 Phase 2b trial for hyperkalemia in diabetic nephropathy and CKD patients

Relypsa, Inc. today announced the start of dosing in a Phase 2b clinical trial of RLY5016 for the treatment of hyperkalemia in patients with diabetic nephropathy and chronic kidney disease (CKD). RLY5016 is a high capacity, non-absorbed, polymer-based potassium binder that is orally administered and has been shown to control serum potassium levels in previous studies.

28 Jun 2011

ChemoCentryx CCX140 Phase II study on type 2 diabetes meets primary endpoint

ChemoCentryx, Inc. today announced that CCX140, the Company's novel, orally active CCR2 antagonist successfully met its primary endpoint of safety and tolerability and demonstrated clinical efficacy in a Phase II study in patients with type 2 diabetes on stable doses of metformin.

28 Jun 2011

Boehringer Ingelheim, Lilly announce new data from linagliptin Phase III study on type 2 diabetes

Boehringer Ingelheim and Eli Lilly and Company today announced Phase III study results for linagliptin, demonstrating improved glycaemic control in adults with type 2 diabetes (T2D) whose blood glucose is not adequately maintained.

27 Jun 2011

Concert to advance CTP-499, C-21191 into Phase 2 trials for diabetic nephropathy and spasticity

Concert Pharmaceuticals, Inc. announced today the advancement of two programs from its DCE Platform. CTP-499 is progressing into Phase 2 clinical trials for diabetic nephropathy and C-21191 has been selected as a lead candidate for spasticity.

20 Jun 2011

Researchers replicate progression of inflammatory gene changes of kidney from mild to severe diabetic nephropathy

University of Louisville researchers have replicated the inflammatory gene changes of a human kidney as it progresses from mild to severe diabetic nephropathy, using a mouse model developed by a UofL researcher, according to an article published today in the journal Experimental Nephrology. Diabetic nephropathy is the foremost cause of kidney failure.

24 May 2011

PVT1 gene may help reduce diabetic nephropathy

A gene called PVT1 may help reduce the kidneys ability to filter blood, leading to kidney disease, kidney failure and death, according to a study published today by researchers at the Translational Genomics Research Institute.

25 Apr 2011

JASN publishes positive results from pirfenidone study in diabetic nephropathy

Researchers at the University of California, San Diego School of Medicine, the National Institutes of Health and the Mayo Clinic have published promising results of a clinical study using an experimental anti-fibrotic and anti-inflammatory drug called pirfenidone to treat patients with diabetic nephropathy. Their study will be published in the April 21 issue of the Journal of the American Society of Nephrology.

22 Apr 2011

Ketogenic diet may reverse impaired kidney function in diabetics

Researchers from Mount Sinai School of Medicine have for the first time determined that the ketogenic diet, a specialized high-fat, low carbohydrate diet, may reverse impaired kidney function in people with Type 1 and Type 2 diabetes. They also identified a previously unreported panel of genes associated with diabetes-related kidney failure, whose expression was reversed by the diet. The findings were published in the current issue of PLoS ONE.

21 Apr 2011